Treatment of Tinea corporis with Unani formulation(Marham-i Hina)
Phase 2
- Conditions
- Health Condition 1: B354- Tinea corporis
- Registration Number
- CTRI/2022/05/042397
- Lead Sponsor
- uqman Unani Medical College Hospital and Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Clinically as well as KOH diagnosed cases of tinea corporis without nail and scalp involvement
2. BSA � 20%
Exclusion Criteria
1. Patients those having treatment history of less than 30 days in case of topical antifungal agent, less than 8 weeks in case of systemic antifungals, and less than 30 days in case of systemic corticosteroids.
2. Pregnant and lactating women.
3. Patients with diabetes mellitus.
4. Patients with known skin allergy.
5. Patients with immunosuppressive disease/drugs.
6. Known cases of any serious illness.
7. Superimposed cases of tinea corporis.
8. Non ââ?¬â??compliance to the trial protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Investigators� global assessment (IGA) of clinical responses. <br/ ><br>2. Mycological cure: Clinically suspected cases of tinea corporis will be <br/ ><br>confirmed by skin scraping and KOH preparation, by visualizing long, <br/ ><br>narrow, septate and branching hyphae under microscope.Timepoint: 1. Before and after the treatment(6th week)
- Secondary Outcome Measures
Name Time Method 1. Change in TCS (Total clinical score) <br/ ><br>2. Change in Dermatology Life Quality IndexTimepoint: At baseline, 14th day, 28th day and after the Completion of study